An official website of the United States government
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
Trial Status: active
The purpose of the study is to assess the efficacy and safety of Acoustic Cluster Therapy
(ACT) when given in addition to chemotherapy for treatment of Locally Advanced Pancreatic
Cancer.
Inclusion Criteria
Inclusion Criteria:
- Not deemed suitable for primary curative surgery and have radiographic and
pathological disease consistent with inoperable LAPC or borderline resectable
pancreatic cancer.
- Suitable to receive treatment with mFOLFIRINOX according to the Investigator's
assessment.
Exclusion Criteria:
• Any prior anti-cancer treatment for pancreatic cancer (e.g. chemotherapy, surgery,
radiation). Palliative bypass procedure and bile duct stenting are allowed.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT06850623.
Locations matching your search criteria
United States
Massachusetts
Boston
Dana-Farber Cancer Institute
Status: Active
Name Not Available
Beth Israel Deaconess Medical Center
Status: Active
Name Not Available
Pennsylvania
Philadelphia
Thomas Jefferson University Hospital
Status: Active
Name Not Available
Patients with Locally Advanced Pancreatic Cancer who have not received prior treatment to
their pancreatic cancer will receive ACT treatment (the drug PS101 and ultrasound
application to the tumor) with up to eight 2-week cycles of modified FOLFIRINOX
chemotherapy.
ACT treatment will be given on Day 1 of each cycle of chemotherapy. Patients' well-being
and side effects will be assessed at the same visits. The objective efficacy of the
treatment will be assessed by CT scans every 8 weeks.
